Last reviewed · How we verify
Tetracycline hydrochloride 3%
At a glance
| Generic name | Tetracycline hydrochloride 3% |
|---|---|
| Also known as | APT™T3X |
| Sponsor | University of Nove de Julho |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Sneeze
- Itch
- Shed tears
- Nasal burning
- Coryza
- Nasal irritation
- Nasal congestion
- Earache
- Nosebleed
- Cough
- Hypotension
- Pain in the face
Key clinical trials
- Antihypertensive Mechanisms of Minocycline in Resistant Hypertension (PHASE4)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma (PHASE2)
- Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry (PHASE4)
- Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury (PHASE2)
- Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg (PHASE4)
- Efficacy of Noisome as A Carrier of Locally Delivered Minocycline Hydrochloride Gel (PHASE2, PHASE3)
- To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetracycline hydrochloride 3% CI brief — competitive landscape report
- Tetracycline hydrochloride 3% updates RSS · CI watch RSS
- University of Nove de Julho portfolio CI